Document is current
Any future updates will be listed below
-
Authors
Pietrobono, Silvia https://orcid.org/0000-0002-5544-7286
De Vita, Veronica https://orcid.org/0009-0001-2606-2977
Mangiameli, Domenico
Aparo, Antonino https://orcid.org/0000-0002-4107-6680
Lorenzo, Eleonora San
Bonato, Alice https://orcid.org/0000-0002-3634-6527
Bertolini, Monica
Scarlato, Enza
Casalino, Simona
Quinzii, Alberto
Zecchetto, Camilla
Melisi, Davide
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (30711)
Ministero della Salute (GR-2016-02361134)
Ministero dell'Istruzione, dell'Università e della Ricerca (PE_00000019)
- License Information
-
More Information
Article History
Received: 14 August 2025
Revised: 11 March 2026
Accepted: 30 March 2026
First Online: 14 April 2026
Competing interests
: Davide Melisi declares that he has received honoraria for lectures and advisory roles from Incyte, Celgene, iOnctura, IQVIA, Eli Lilly, Evotec, MSD, Personal Genomics, Shire, Roche, Baxter, Servier, AstraZeneca, Taiho Pharmaceutical, Terumo, Viatris, Pegascy, GSK, Revolution Medicine and research funding from Celgene, Evotec, Incyte, iOnctura, Roche, Servier. The other authors have declared that no conflict of interest exists.
